<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00658437</url>
  </required_header>
  <id_info>
    <org_study_id>CY503C1</org_study_id>
    <secondary_id>EudraCT no. 2007-000427-17</secondary_id>
    <nct_id>NCT00658437</nct_id>
  </id_info>
  <brief_title>CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy</brief_title>
  <official_title>A Phase II Multicenter Study to Test Progression-free and Overall Survival of CY-503 in the Treatment of Patients With Unresectable Stage IV Metastatic Melanoma After Antineoplastic Treatment Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytavis Biopharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytavis Biopharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is designed as a phase II evaluation of the effect of CY-503 on progression free
      survival (PFS) in patients with stage IV malignant melanoma after failure of prior therapy.
      The aim of the study is at least a rate of 25% (PFS &gt;/= 3 months).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor assessment by CT and MRT</measure>
    <time_frame>each 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological response (e.g. measurement of cytokines in serum)</measure>
    <time_frame>each 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life using a standardized questionnaire</measure>
    <time_frame>each 4 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CY-503</intervention_name>
    <description>solution for subcutaneous injection, 350 ng twice weekly</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed, unresectable, Stage IV metastatic melanoma

          -  Failure of prior chemotherapy and / or immunotherapy based regimen

          -  Measurable disease (based on RECIST criteria)

          -  Males and females of at least 18 years of age

          -  Women of reproductive potential (defined as being &lt;1 year post-menopausal) must have a
             negative pregnancy test within 3 days prior to randomization; and men and women of
             reproductive potential must agree to practice an effective method of avoiding
             pregnancy

          -  Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.

          -  Life expectancy of at least 3 months

          -  WBC ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,500/mm3, platelet count
             ≥100,000/mm3

          -  Bilirubin ≤ 1.5 mg/dL (25.65 μmol/L) (unless due to Gilbert's syndrome in which case
             the bilirubin should be ≤3.5 mg/dL (59.86 μmol/L)), aspartate transaminase
             (AST)/alanine transaminase (ALT) ≤ 3 × upper limit of normal (ULN); hepatic alkaline
             phosphatase ≤ 3.0 × ULN

          -  LDH ≤ 2.5 upper limit of normal (ULN)

          -  Serum creatinine ≤ 1.5 mg/dL (132.60 μmol/L), proteinuria &lt; 2.0 g/24 hr urine

          -  Patients who have had prior treatment with adjuvant or palliative immunotherapy are
             eligible provided that therapy ended at least 1 month prior to randomization and all
             treatment-related toxicities have resolved

          -  Patients with bone metastasis should be evaluated by the investigator and prior
             treatment should be finished at least 1 month prior to randomization

          -  Prior radiotherapy (for palliative care only) is allowed provided there is
             measurable/evaluable disease outside of the radiation field and all radiation-related
             toxicities have resolved; if there is only one measurable lesion it may not have been
             irradiated unless subsequent progression has been documented

          -  Patients who had prior major surgery are eligible if at least 4 weeks have passed
             since their surgery and all surgical wounds have healed prior to randomization and at
             least one measurable tumor is present

          -  All toxicities related to prior adjuvant therapy must have resolved

          -  Written informed consent

        Exclusion Criteria:

          -  Pregnancy or nursing

          -  Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy
             for treatment of cancer

          -  Current or planned participation in a research protocol

          -  Received an investigational agent within 4 weeks prior to randomization

          -  Brain metastases or primary brain tumors, symptomatic pleural effusion or ascites
             requiring paracentesis

          -  Ocular melanoma

          -  History of prior malignancies within the past 5 years other than non-melanomatous skin
             cancers that have been controlled, carcinoma in situ of the cervix, T1a or b prostate
             cancer noted incidentally during a transurethral resection of prostate (TURP) with
             prostate-specific antigen (PSA) values within normal limits since TURP, or superficial
             bladder cancer

          -  Any evidence of or history elicited by the investigator of symptomatic cerebrovascular
             events within 6 months prior to randomization; or any history or evidence of pulmonary
             embolism or thrombophlebitis requiring anticoagulant therapy

          -  Any current evidence of hematemesis, melena, hematochezia, or gross hematuria

          -  Elective surgery planned during the study period through 30 days after the last dose
             of CY-503

          -  History of hypersensitivity to previously administered mistletoe

          -  Prior therapy with mistletoe

          -  History of primary immunodeficiency

          -  Known human immunodeficiency virus (HIV) or known active viral hepatic infections

          -  Prior treatment with CY-503

          -  A general medical or psychological condition or behaviour in the opinion of the
             investigator, might not permit the patient to complete the study or sign the informed
             consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Mohr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elbe Klinikum Buxtehude, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haut Tumor Zentrum Charité</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologisches Zentrum Elbe-Klinikum Buxtehude</name>
      <address>
        <city>Buxtehude</city>
        <zip>D-21603</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautklinik Linden MH Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Hautklinik Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2008</study_first_submitted>
  <study_first_submitted_qc>April 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2008</study_first_posted>
  <last_update_submitted>June 7, 2011</last_update_submitted>
  <last_update_submitted_qc>June 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Cytavis Biopharma GmbH</name_title>
    <organization>Industry</organization>
  </responsible_party>
  <keyword>Melanoma, Stage IV, Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

